News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|August 2, 2015

Learning About Your Prognosis

Episodes in this series

EP. 1 Being Diagnosed With Cancer

EP. 1 Being Diagnosed With Cancer

EP. 2 Talking to Your Doctor About Your Diagnosis

EP. 2 Talking to Your Doctor About Your Diagnosis

EP. 3 Learning About Your Prognosis

EP. 3 Learning About Your Prognosis

EP. 4 Cancer and Family Matters

EP. 4 Cancer and Family Matters

EP. 5 Myths About Cancer and Treatment

EP. 5 Myths About Cancer and Treatment

EP. 6 Logistics, Appointments, and Clinical Trials

EP. 6 Logistics, Appointments, and Clinical Trials

Newsletter

Stay up to date on cancer updates, research and education

Related Content

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

ByJason Broderick

December 8th 2025

Dr. Robert Orlowski, chairman, Ad Interim; director of Myeloma; and professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

ByDr. Robert Orlowski

December 8th 2025

Georgia Hurst is a fierce patient advocate for those with Lynch syndrome. Catch up on all of Georgia's blogs here!

What I Want You to Know about Lynch Syndrome

ByGeorgia Hurst

December 8th 2025

CLL

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

ByJason M Broderick

December 7th 2025

follicular lymphoma

Epkinly Combo Effective in Second-Line R/R Follicular Lymphoma

December 7th 2025

Trending on CURE

A New Option Without Traditional Chemotherapy for Ph+ ALL

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

Elrexfio Maintains Responses in Elderly, Frail Patients With Multiple Myeloma

Epkinly Combo Effective in Second-Line R/R Follicular Lymphoma

© 2025 MJH Life Sciences^®

All rights reserved.